Rob Collin
Company: Astherna BV
Job title: Chief Scientific Officer
Seminars:
Advancing ASO Therapies for Ophthalmic Disorders: Addressing Challenges & Expanding Applications in Ophthalmology 9:00 am
Overview of antisense oligonucleotides (ASOs) and their role in treating ophthalmic disorders Exploring the potential of ASOs in broader applications beyond splicing modulation Overview of recent advancements in ASO design and delivery methods Highlighting efforts in developing functional assays and organoid models for assessing ASO efficacyRead more
day: Day One 11th